MiR-132 also inhibits proliferation in hepatocellular carcinoma (HCC) by inactivating the AKT / mTOR signaling pathway [22], and by inhibiting IL1β and IL6 expression through inhibition of the transcriptional co-activator P300 [23]. This evidence concerns the gene MTOR and hepatocellular carcinoma.